We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+14.83%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$15.3M
Cap. Flow
+$36.9M
Cap. Flow %
30.81%
Top 10 Hldgs %
93.81%
Holding
21
New
1
Increased
2
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$48.6M
2
OCGN icon
Ocugen
OCGN
+$1.65M
3
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
+$757K

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$9.29M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.16M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$1.38M
4
RGLS
Regulus Therapeutics
RGLS
+$1.08M
5
ACHV icon
Achieve Life Sciences
ACHV
+$195K

Sector Composition

Rank Sector Weight
1 Healthcare 94.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.73B
$52M 43.5%
+2,601,814
New +$48.6M
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$20M 16.7%
1,301,413
– –
SIEN
3
DELISTED
Sientra, Inc.
SIEN
$18.7M 15.62%
219,901
– –
NOVN
4
DELISTED
Novan, Inc. Common Stock
NOVN
$5.38M 4.49%
20,000
– –
CHMA
5
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.95M 3.3%
2,080,595
– –
TARA icon
6
Protara Therapeutics
TARA
$220M
$3.63M 3.04%
50,447
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$2.72M 2.27%
1,600,000
– –
DERM
8
DELISTED
Dermira, Inc.
DERM
$2.12M 1.77%
70,000
– –
EVAR
9
DELISTED
Lombard Medical, Inc.
EVAR
$2.03M 1.7%
3,473,452
– –
CLLS
10
Cellectis
CLLS
$277M
$1.69M 1.41%
100,000
– –
OCGN icon
11
Ocugen
OCGN
$416M
$1.44M 1.2%
14,815
+11,867
+403% +$1.65M
SENS icon
12
Senseonics Holdings Inc
SENS
$263M
$1.38M 1.15%
25,844
– –
ANTH
13
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.17M 0.98%
107,715
+43,710
+68% +$757K
IMDZ
14
DELISTED
Immune Design Corp.
IMDZ
$1.07M 0.9%
197,300
– –
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
$1M 0.84%
250,000
– –
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$973K 0.81%
337,825
-607,932
-64% -$2.16M
INNL
17
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$360K 0.3%
537,235
-18,320
-3% -$68K
ACHV icon
18
Achieve Life Sciences
ACHV
$659M
– –
-180
Closed -$195K
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-437,994
Closed -$1.38M
RGLS
20
DELISTED
Regulus Therapeutics
RGLS
– –
-2,728
Closed -$1.08M
CEMP
21
DELISTED
Cempra, Inc.
CEMP
– –
-383,935
Closed -$9.29M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2016 Portfolio in Review

As of Q4 2016, Abingworth held 21 positions worth $120M, up 15% from $104M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Abingworth deployed $36.9M of net new capital in Q4 2016, opening 1 new position and adding to 2 existing holdings. Its largest new stake was CRISPR Therapeutics: 2,601,814 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Dicerna Pharmaceuticals, Inc., an estimated $2.16M trimmed.

  • Abingworth's largest Q4 2016 buy was CRISPR Therapeutics: 2,601,814 shares worth $52M.
  • Abingworth added most to Ocugen in Q4 2016, an estimated $1.65M increase.
  • Abingworth's biggest Q4 2016 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $2.16M.
  • Abingworth fully exited Cempra, Inc. in Q4 2016, selling an estimated $9.29M.
  • Abingworth's ten largest holdings make up 94% of its $120M portfolio in Q4 2016.
  • Abingworth opened 1 new position and closed 4 in Q4 2016.
  • Abingworth's portfolio value rose 15% quarter-over-quarter to $120M.

Based on Abingworth's 13F filing for Q4 2016, filed 14 Feb 2017.